Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M

CASTLE BIOSCIENCES INC

2024-Q3 EPS reported $0.30 revenue$245,758,000

Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.
Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.
Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.
Q3 operating cash flow $23.3M vs $5.0M prior year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.